Company
Headquarters: New Haven, CT, United States
Employees: 89
CEO: Dr. Vimal D. Mehta Ph.D.
$37.2 Million
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $1.4 M |
| EBITDA | $-167,300,992 |
| Gross Profit TTM | $120,000 |
| Profit Margin | 8.70% |
| Operating Margin | -5285.90% |
| Quarterly Revenue Growth | 58.00% |
BioXcel Therapeutics, Inc. has the following listings and related stock indices.
Stock: NASDAQ: BTAI
Stock: FSX: BX2